Skip to content

daxin EF-808NBS

by Guangzhou Daxin Health Technology Co., Ltd.

daxin EF-808NBS is a bioelectrical body composition analyser (FDA Class II; FDA product code PUH, Analyzer, Body Composition, Exempt) made by Guangzhou Daxin Health Technology Co., Ltd., listed in FDA GUDID since 24 Jun 2021 (UDI-DI 06974239700007), registry data as of 22 Oct 2026.

Listed FDA GUDID listing, no authorization on record

Valid until

Not applicable

Database listing, no authorization

FDA recalls

Not checked

No FDA submission to match recalls against

Documents

None

No authorization documents

Trust

Unverified

Source GUDID, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number06974239700007 UDI-DI Date24 Jun 2021ListedStatusListed GUDID: in commercial distribution

Official records

From the FDA record

Device description
Body Composition Scale EF-808NBS
MRI safety
MR Unsafe
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 22 Oct 2026, as the labeller entered it.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — GUDID listing Listed

Specification

GUDID

Trade name
daxin
Generic name
Bioelectrical body composition analyser
Model / reference
EF-808NBS
Description
Body Composition Scale EF-808NBS
Primary DI / UDI-DI
06974239700007
FDA product code
PUH
GMDN term
Bioelectrical body composition analyser
Device class
Class II
Regulation number
870.2770
GUDID distribution status
In Commercial Distribution
MRI safety
MR Unsafe

Similar devices in this category

Other devices filed under Bioelectrical body composition analyser.

Other devices from Guangzhou Daxin Health Technology Co., Ltd.

See all devices from Guangzhou Daxin Health Technology Co., Ltd. →

Properties

  • Single use
  • Premarket exempt
  • Lot / batch number
  • Manufacturing date
Other properties (11, all answered No)